C30 – Biosimilars: Market access challenges and opportunities

10 years’ experience with biosimilars in Europe has demonstrated the need for policies to support uptake and this session will explore the opportunities and challenges for biosimilar market access here in Australia.   From both a government and industry perspective, the speakers will explore a range of topics including biosimilar marketing and pricing, reimbursement challenges, ‘a’ flagging for pharmacy substitution, uptake drivers, and the government’s Biosimilar Awareness Initiative.  The audience will leave the session with a broad appreciation of how the Australian biosimilars market has formed to date and how we compare to international markets, as well as an understanding of the reimbursement challenges and opportunities for biosimilars.

 

Chairperson: Belinda Wood, CEO, GBMA